SCHEMBL4249824

SCHEMBL4249824

Fc1ccc(-c2n[nH]cc2CN2CCN(c3nccc(C(F)(F)F)n3)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.52
ADRB1 P08588 1/20 0.48
KMT2A Q03164 1/20 0.48
PKM P14618 2/20 0.45
SLC6A7 Q99884 1/20 0.43
KDM4E B2RXH2 3/20 0.43
ACHE P22303 2/20 0.42
DRD2 P14416 2/20 0.42
DRD4 P21917 2/20 0.42
DRD3 P35462 2/20 0.42
POLB P06746 1/20 0.40
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RBP4 P02753 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4249777 0.86 KDM4E (0.59) HTR1AKMT2AKDM4EDRD2DRD4
SCHEMBL4248453 0.80 KDM4E (0.52) HTR1AADRB1KDM4EDRD2DRD4
SCHEMBL4253037 0.79 MAPT (0.60) HTR1AKDM4EDRD2DRD4DRD3
SCHEMBL4245485 0.78 HSD11B1 (0.56) HTR1AHSD17B10RBP4MAPT
SCHEMBL4240754 0.78 MAPT (0.53) HTR1AKDM4EDRD2DRD4DRD3
SCHEMBL4252062 0.77 KDM4E (0.59) HTR1AKDM4EACHEDRD2DRD4
SCHEMBL4252387 0.76 SMN1; SMN2 (0.53) KMT2APKMKDM4EDRD4MAPT
SCHEMBL4252187 0.76 KDM4E (0.52) HTR1AKDM4EDRD2DRD4DRD3
SCHEMBL4251252 0.76 DRD4 (0.59) HTR1APKMKDM4EDRD2DRD4
SCHEMBL4246303 0.74 HTR1A (0.45) HTR1AKMT2AKDM4EDRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2009-12-10 US claimed
CN-101490010-A Compounds and compositions as ITPKB inhibitors IRM LLC (VG) 2009-07-22 CN claimed
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2009-12-10 US disclosed
CN-101490010-A Compounds and compositions as ITPKB inhibitors IRM LLC (VG) 2009-07-22 CN disclosed
EP-2057124-A2 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM, LLC (BM) 2009-05-13 EP disclosed
WO-2008011611-A2 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IP6K1, IP6K2, IP6K3 HTR1A 4659/4885ADRB1 3453/4885KMT2A 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.